Audited Financial Statements for the quarter and year ended on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shukra Pharmaceuticals reported FY25 revenue from operations of Rs 3,258.73 lakhs, down sharply by about 56% from Rs 7,457.29 lakhs in FY24. Net profit for the year fell to Rs 957.51 lakhs from Rs 1,853.72 lakhs, a decline of around 48%, translating to EPS of Rs 0.22 versus Rs 4.23 last year. For Q4 FY25 alone, revenue grew nearly 22% year-on-year to Rs 1,326.98 lakhs and net profit rose to Rs 538.64 lakhs. Total assets stood at Rs 8,676.98 lakhs with healthy equity of Rs 6,283.59 lakhs and very low borrowings of about Rs 418 lakhs. Operating cash flow turned positive at Rs 791.84 lakhs against a negative Rs 519.68 lakhs in FY24. The statutory auditor MAAK and Associates issued an unmodified (unqualified) opinion with no emphasis of matter.
The sharp year-on-year revenue and profit collapse in FY25 is a red flag despite the strong sequential Q4 recovery and clean audit report, suggesting investors should examine whether the business model or operations underwent a major change. Stock price may remain under pressure until the company clarifies the revenue drop and demonstrates a sustained recovery into FY26.